Skip to content

Safety and efficacy of Alfentanil combined with remimazolam in outpatient painless abortion

Safety and efficacy of Alfentanil combined with remimazolam in outpatient painless abortion

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094571
Enrollment
Unknown
Registered
2024-12-24
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early pregnancy

Interventions

Experimental group (Group A):Intravenous injection of remimazolam 0.3 mg/kg and alfentanil 10 µg/kg
Control group (Group B):Intravenous injection of remimazolam 0.3 mg/kg and fentanyl 1 µg/kg

Sponsors

Mianyang 404 Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1:   Age range: 18-45 years old 2:   Gestational age = 10 weeks 3:   ASA rating ranges from Level I to Level II 4:   BMI ranges from 18kg/m2 to 25 kg/m2 5:   Voluntary acceptance of outpatient painless abortion procedure 6: Preoperative routine examinations of liver and kidney function, electrolytes, etc. showed no abnormalities

Exclusion criteria

Exclusion criteria: 1: Individuals who are allergic or have contraindications to opioid and benzodiazepine drugs 2: History of acute respiratory inflammation within two weeks without recovery 3: History of poor recovery from previous surgical anesthesia 4: electrolyte disturbance 5: Combination use of other types of sedatives and analgesics before surgery 6: Researchers believe that patients should not participate in this trial

Design outcomes

Primary

MeasureTime frame
HR, MAP, SpO2;

Secondary

MeasureTime frame
Induction time of intravenous anesthesia;Wake-up time;VAS at awakening, VAS at 15 minutes of awakening, VAS at 30 minutes of awakening;Departure time from the hospital;

Countries

China

Contacts

Public ContactZhang Weijie

Mianyang 404 Hospital

864979811@qq.com+86 177 4544 0200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 11, 2026